Single Therapeutic and Supratherapeutic Doses of Sacubitril/Valsartan (LCZ696) Do Not Affect Cardiac Repolarization

European Journal of Clinical Pharmacology - Germany
doi 10.1007/s00228-016-2062-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Single Therapeutic and Supra‐Therapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial

Clinical Pharmacology and Therapeutics
Pharmacology
2019English

LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis and Vasculopathy in a Rat Model of Chronic Kidney Disease

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2018English

Potential Markers of Sacubitril-Valsartan Tolerance

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Sacubitril/Valsartan Use for the Hospitalist

American Journal of Hospital Medicine
2017English

Sacubitril/Valsartan: Beyond Natriuretic Peptides

Heart
Cardiovascular MedicineCardiology
2017English

Sacubitril-Valsartan in Heart Failure and Multimorbidity Patients

ESC heart failure
Cardiovascular MedicineCardiology
2018English

Sacubitril/Valsartan Verbessern Auch Den HbA1c-Wert

MMW Fortschritte der Medizin
Medicine
2017English

Bedtime Doses of Prazosin Do Not Affect Daytime Salivary Amylase Markers in PTSD

Heliyon
Multidisciplinary
2019English

Sacubitril/Valsartan: Evaluation of Safety and Efficacy as an Antihypertensive Treatment

Drugs in Context
Molecular MedicinePharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy